Network Bio launched with $50 million in financing and announced a collaboration valued at $30 million with Nvidia to develop a cell-free RNA (cfRNA) foundation model. The partnership aims to create a population-scale model that can support downstream supervised models for oncology and non-oncology applications. The startup plans to train on large-scale tissue, blood, molecular, and longitudinal clinical outcome datasets contributed via collaborations with academic medical centers including Mass General Brigham, the University of Pennsylvania, and the University of Colorado Anschutz. Network Bio will combine these datasets with Nvidia tools such as Parabricks and BioNeMo Recipes and intends to streamline the conversion of biobank access into model-ready data. This is a concrete bet on cfRNA as a scalable biomarker substrate for both discovery and drug development, with model outputs intended to feed areas like biomarker finding and disease detection. In a market increasingly focused on compute-and-data platforms, the credibility signal will be whether the foundation model delivers usable predictive performance across new datasets.